gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.
Company profile
Ticker
GRTS
Exchange
Website
CEO
Andrew Allen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Gritstone Oncology, Inc.
SEC CIK
GRTS stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
2 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
424B5
Prospectus supplement for primary offering
1 Apr 24
8-K
Other Events
1 Apr 24
S-8
Registration of securities for employees
5 Mar 24
8-K
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
5 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Cost Associated with Exit or Disposal Activities
29 Feb 24
8-K
Results of Operations and Financial Condition
12 Feb 24
EFFECT
Notice of effectiveness
2 Jan 24
Latest ownership filings
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
Frazier Life Sciences Public Fund, L.P.
13 Feb 24
SC 13G
MORGAN STANLEY
8 Feb 24
4
Matthew Hawryluk
5 Feb 24
4
Erin Jones
5 Feb 24
4
Vassiliki Economides
5 Feb 24
4
Karin Jooss
5 Feb 24
4
James Cho
5 Feb 24
4
Andrew R Allen
5 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 36.07 mm | 36.07 mm | 36.07 mm | 36.07 mm | 36.07 mm | 36.07 mm |
Cash burn (monthly) | 4.36 mm | 3.40 mm | 12.87 mm | 11.76 mm | 10.36 mm | 11.04 mm |
Cash used (since last report) | 28.80 mm | 22.51 mm | 85.06 mm | 77.71 mm | 68.50 mm | 73.00 mm |
Cash remaining | 7.27 mm | 13.56 mm | -48.99 mm | -41.64 mm | -32.43 mm | -36.93 mm |
Runway (months of cash) | 1.7 | 4.0 | -3.8 | -3.5 | -3.1 | -3.3 |
Institutional ownership, Q3 2023
57.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 92 |
Opened positions | 10 |
Closed positions | 9 |
Increased positions | 26 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 83.37 bn |
Total shares | 56.67 mm |
Total puts | 57.60 k |
Total calls | 89.30 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Redmile | 8.51 mm | $14.64 bn |
BLK Blackrock | 6.09 mm | $10.47 bn |
Point72 Asset Management | 5.92 mm | $10.19 bn |
Frazier Life Sciences Public Fund | 4.13 mm | $0.00 |
Vanguard | 4.06 mm | $6.98 bn |
Versant Venture Management | 3.56 mm | $6.13 bn |
Versant Venture Capital V | 2.90 mm | $0.00 |
Avidity Partners Management | 2.73 mm | $4.70 bn |
Balyasny Asset Management | 2.04 mm | $3.51 bn |
Geode Capital Management | 1.77 mm | $3.04 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Feb 24 | Allen Andrew R | Common Stock | Grant | Acquire A | No | No | 0 | 105,000 | 0.00 | 899,345 |
1 Feb 24 | Allen Andrew R | Stock Option Common Stock | Grant | Acquire A | No | No | 2.46 | 615,000 | 1.51 mm | 615,000 |
1 Feb 24 | James Cho | Common Stock | Grant | Acquire A | No | No | 0 | 18,000 | 0.00 | 138,644 |
1 Feb 24 | James Cho | Stock Option Common Stock | Grant | Acquire A | No | No | 2.46 | 109,000 | 268.14 k | 109,000 |
1 Feb 24 | Jooss Karin | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 648,851 |
1 Feb 24 | Jooss Karin | Stock Option Common Stock | Grant | Acquire A | No | No | 2.46 | 235,000 | 578.10 k | 235,000 |
1 Feb 24 | Vassiliki Economides | Common Stock | Grant | Acquire A | No | No | 0 | 35,000 | 0.00 | 227,762 |
1 Feb 24 | Vassiliki Economides | Stock Option Common Stock | Grant | Acquire A | No | No | 2.46 | 215,000 | 528.90 k | 215,000 |
1 Feb 24 | Erin Jones | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 324,618 |
1 Feb 24 | Erin Jones | Stock Option Common Stock | Grant | Acquire A | No | No | 2.46 | 235,000 | 578.10 k | 235,000 |
News
Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study Of "Off-the-Shelf" Neoantigen Vaccine Platform
15 Apr 24
Nasdaq Down Over 1%; VivoPower International Shares Spike Higher
2 Apr 24
JMP Securities Maintains Market Outperform on Gritstone Bio, Raises Price Target to $5
2 Apr 24
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
2 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
2 Apr 24
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
16 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
12 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
8 Apr 24
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
8 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
4 Apr 24